Company Filing History:
Years Active: 2024-2025
Title: The Innovative Contributions of Andrew Creese
Introduction
Andrew Creese is a notable inventor based in Abingdon, GB. He has made significant contributions to the field of biotechnology, particularly in the development of binding molecules for therapeutic applications. With a total of 3 patents to his name, Creese's work is paving the way for advancements in the treatment of malignant diseases.
Latest Patents
Creese's latest patents focus on binding molecules that incorporate T cell receptor (TCR) variable domains. One of his inventions relates to binding molecules that can bind to a PIWIL1 peptide-HLA complex, which has potential applications in treating malignant diseases. Another patent involves binding molecules that target a PRAME peptide-HLA complex, specifically binding to the sequence PYLGQMINL in complex with HLA-A24. These innovations highlight his commitment to addressing critical health challenges.
Career Highlights
Andrew Creese is currently associated with Immunocore Limited, a company known for its pioneering work in immunotherapy. His role at the company allows him to collaborate with other experts in the field, further enhancing the impact of his inventions.
Collaborations
Some of his notable coworkers include Nathaniel Ross Liddy and Chandramouli Reddy Chillakuri. Their collective expertise contributes to the innovative environment at Immunocore Limited.
Conclusion
In summary, Andrew Creese's contributions to biotechnology through his patents and work at Immunocore Limited are significant. His focus on binding molecules for the treatment of malignant diseases showcases his dedication to advancing medical science.